Marta Bonotto
Udine, 33100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications
Time-varying hazard rates reveal patterns of progression in HR+/HER2- metastatic breast cancer: Towards risk-adapted monitoring.
Journal: Translational oncology
Published: July 06, 2026
Prognostic and predictive value of HRD in early triple negative breast cancer (TNBC).
Journal: Critical reviews in oncology/hematology
Published: August 07, 2025
Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study.
Journal: Breast (Edinburgh, Scotland)
Published: June 24, 2025
Corrigendum to "Antibody-Drug conjugates in elderly patients with breast cancer" [The Breast 80 (2025) 104428].
Journal: Breast (Edinburgh, Scotland)
Published: March 14, 2025
Antibody-drug conjugates in elderly patients with breast cancer.
Journal: Breast (Edinburgh, Scotland)
Published: December 18, 2024
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics.
Journal: Translational oncology
Published: December 15, 2024
CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature.
Journal: Current oncology (Toronto, Ont.)
Published: November 03, 2022
Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?
Journal: Frontiers in oncology
Published: February 28, 2022
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation.
Journal: The oncologist
Published: July 20, 2021
Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer.
Journal: Cancers
Published: May 20, 2021
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
Journal: ESMO open
Published: December 28, 2020
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.
Journal: Breast (Edinburgh, Scotland)
Published: November 17, 2020
Last Updated: 09/26/2026